Latest News: Xantho Biotechnology Participates in 2025 Bio-Europe Conference, Actively Expanding International Licensing and Collaboration for GM-XANTHO
The current Bio-Europe conference was held from November 3 to 5, 2025, at the Vienna Exhibition & Congress Center in Austria.
Our company sent representatives to attend the event, with the core objective of advancing the international out-licensing process for our new botanical drug, GM-XANTHO.
During the conference, our company primarily focused on the following key areas:
• International Licensing Expansion: actively expanding international licensing opportunities for the GM-XANTHO topical cream for the treatment of atopic dermatitis.
• Joint Development Discussions: conducting one-on-one meetings with several interested European pharmaceutical companies to discuss cooperation for the joint development of the GM-XANTHO Phase 2b clinical trial for atopic dermatitis.
• Deepening International Exchange: held in-depth meetings with several international pharmaceutical companies interested in botanical new drug development, fostering potential future collaboration.
Looking ahead, our company will continue to plan and advance the international new drug licensing process based on the latest market landscape and evolving trends.
We aim to leverage the power of international collaboration to accelerate the development of GM-XANTHO, hoping to bring novel treatment options to patients suffering from atopic dermatitis globally at an early date.
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
